Precision targeting tumor cells using cancer-specific InDel mutations with CRISPR-Cas9.

Area of Science:

• Oncology
• Molecular Biology
• Gene Editing

Background:

• Achieving selective cancer cell death remains a significant challenge due to shared features between cancer and normal cells.
• Current therapeutic strategies often struggle to differentiate and eliminate cancerous cells without causing collateral damage to healthy tissues.

Purpose of the Study:

• To develop a novel cancer therapeutic strategy for selective cancer cell elimination.
• To utilize the CRISPR-Cas system for inducing cancer-specific cell death through DNA double-strand breaks (DSBs).

Main Methods:

• Developed the cancer-specific insertions-deletions (InDels) attacker (CINDELA) strategy.
• Employed CRISPR-Cas9 technology to introduce multiple DNA DSBs specifically in cancer cells.
• Targeted cancer-specific InDels to trigger selective cell death pathways.

Main Results:

• CINDELA demonstrated selective killing of human cancer cell lines in vitro.
• The strategy effectively eradicated xenograft human tumors in mice.
• CINDELA showed efficacy in patient-derived glioblastoma and lung cancer xenograft models.
• No adverse effects were observed in healthy human cells or on mouse growth.

Conclusions:

• CINDELA represents a novel and effective strategy for cancer therapy by leveraging CRISPR-mediated DSBs.
• The approach offers high specificity, targeting cancer cells while sparing normal tissues.
• This proof-of-concept study validates CINDELA's potential for clinical translation in treating various cancers.